Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
Launched by NATIONAL CANCER INSTITUTE (NCI) · May 8, 2012
Trial Information
Current as of July 04, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how certain biological markers, known as biomarkers, can help doctors predict how well patients with early-stage non-small cell lung cancer (NSCLC) respond to treatment after they have received chemotherapy. By examining samples of tissue from patients who have already been treated, researchers hope to understand changes in DNA that could provide insights into cancer behavior and treatment outcomes. This study aims to improve future treatment decisions for patients with NSCLC.
To be eligible for this trial, participants need to have had early-stage NSCLC and received specific types of chemotherapy as part of previous pivotal studies. The trial is open to both men and women aged 65 to 74. Although the trial is not yet recruiting participants, those who do take part can expect to contribute to important research that may enhance treatment options for future patients with lung cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Samples from patients treated in 4 adjuvant chemotherapy (ACT) for early-stage non-small cell lung cancer (NSCLC) pivotal trials:
- • International Adjuvant Lung Cancer Trail (IALT)
- • Cancer and Leukemia Group B (CALGB)-9633
- • CAN-NCIC-BR10
- • Adjuvant Navelbine International Trialist Association (ANITA)
- • Not specified
- • See Disease Characteristics
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kingston, Ontario, Canada
Patients applied
Trial Officials
Lesley Seymour
Principal Investigator
Canadian Cancer Trials Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials